JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 103 filers reported holding JOUNCE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $273,000 | +145.9% | 40,853 | +282.9% | 0.00% | – |
| Q1 2021 | $111,000 | -89.8% | 10,669 | -92.9% | 0.00% | -100.0% |
| Q4 2020 | $1,086,000 | +7.6% | 150,731 | +38.2% | 0.00% | 0.0% |
| Q3 2020 | $1,009,000 | +34.0% | 109,061 | -7.6% | 0.00% | 0.0% |
| Q2 2020 | $753,000 | +50.9% | 118,074 | +5.5% | 0.00% | 0.0% |
| Q1 2020 | $499,000 | +2395.0% | 111,875 | +4901.1% | 0.00% | – |
| Q4 2019 | $20,000 | +300.0% | 2,237 | +56.1% | 0.00% | – |
| Q3 2019 | $5,000 | -44.4% | 1,433 | -24.5% | 0.00% | – |
| Q2 2019 | $9,000 | +125.0% | 1,898 | +222.2% | 0.00% | – |
| Q1 2019 | $4,000 | +300.0% | 589 | +181.8% | 0.00% | – |
| Q4 2018 | $1,000 | -50.0% | 209 | +2.0% | 0.00% | – |
| Q3 2018 | $2,000 | 0.0% | 205 | -1.4% | 0.00% | – |
| Q2 2018 | $2,000 | – | 208 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 9,200,349 | $64,402,000 | 44.86% |
| TRV GP III, LLC | 3,048,780 | $21,342,000 | 1.83% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 406,665 | $2,847,000 | 1.65% |
| Sofinnova Investments, Inc. | 925,280 | $6,477,000 | 0.39% |
| Omega Fund Management, LLC | 334,965 | $2,345,000 | 0.35% |
| Yorktown Management & Research Co Inc | 49,200 | $344,000 | 0.31% |
| Woodline Partners LP | 940,902 | $6,586,000 | 0.18% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 51,000 | $357,000 | 0.09% |
| HORIZON FINANCIAL SERVICES, LLC | 12,005 | $84,000 | 0.08% |
| Gyon Technologies Capital Management, LP | 26,893 | $188,000 | 0.06% |